Orexigen (OREX) Pops Higher as Contrave May Get Speedier Approval (VVUS) (ARNA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Obesity Pill Pharma Gear Up to Report Q3 Results Next Week (ARNA) (OREX) (VVUS)
October 31, 2012 12:31 PM EDTObesity pill makers are girding for an exciting few days early next week.
Announced today, Orexigen (Nasdaq: OREX) will be releasing third-quarter results on November 7th, after U.S. markets close. Peer VIVUS (Nasdaq: VVUS) will be... More
Jefferies Boosts Target on Orexigen (OREX) as FDA Gets Close to Admitting Error
October 23, 2012 7:42 AM EDTJefferies raised its price target on Orexigen Therapeutics (NASDAQ: OREX) from $5 to $6 - but kept its Hold rating - after the FDA indicated it may allow Contrave's resubmission before the LIGHT interim data AND with LIGHT running well ahead of schedule, we now... More
Orexigen (OREX) to Provide Light and Study Update Oct. 22nd
October 19, 2012 4:04 PM EDTOrexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call and webcast Monday, October 22, 2012, at 8:30 a.m. Eastern Time to provide a Company and Light Study update.
To listen to the conference call, please dial:866-700-6293 from the United States and... More
